TxCell develops cellular immunotherapy platforms based on antigen-specific regulatory T cells for the treatment of severe autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders.

Type
Public
HQ
Valbonne, FR
Founded
2001
Size (employees)
57 (est)+10%
Website
txcell.com
TxCell was founded in 2001 and is headquartered in Valbonne, FR
Report incorrect company information

Key People/Management at TxCell

Stéphane Boissel

Stéphane Boissel

CEO
Raphaël Flipo

Raphaël Flipo

SVP & CFO
Francois Meyer

Francois Meyer

Chairman of the Board and Head of Research

TxCell Office Locations

TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
Show all (1)
Report incorrect company information

TxCell Financials and Metrics

TxCell Financials

TxCell's revenue was reported to be €2.95 m in FY, 2016 which is a 36.4% decrease from the previous period.
EUR

Revenue (FY, 2016)

2.9 m

Revenue growth (FY, 2015 - FY, 2016), %

(36.4%)

Net income (FY, 2016)

(13.6 m)

EBIT (FY, 2016)

(12.8 m)

Market capitalization (31-Oct-2017)

31.3 m

Closing share price (31-Oct-2017)

1.6

Cash (31-Dec-2016)

3.5 m

EV

33 m
TxCell's current market capitalization is €31.3 m.
EURFY, 2014FY, 2015FY, 2016

Revenue

3.4 m4.6 m2.9 m

Revenue growth, %

36%(36%)

General and administrative expense

2.2 m3.5 m4.5 m

R&D expense

7.8 m10.8 m10.5 m
EURFY, 2014FY, 2015FY, 2016

Cash

13.9 m9.2 m3.5 m

Accounts Receivable

1 m4 k4 k

Current Assets

18.5 m13.8 m5.8 m

PP&E

1.4 m876 k736 k
EURFY, 2014FY, 2015FY, 2016

Net Income

(8.3 m)(11.3 m)(13.6 m)

Depreciation and Amortization

460 k1.1 m(326 k)

Accounts Payable

5.8 m213 k(714 k)

Cash From Operating Activities

(6.9 m)(10.1 m)(10.4 m)
EURY, 2016

EV/EBIT

-2.6 x

EV/CFO

-3.2 x

Revenue/Employee

61.4 k

Debt/Equity

4.4 x

Debt/Assets

0.4 x

Financial Leverage

10.7 x
Show all financial metrics
Report incorrect company information